Alphabet-backed start-up Isomorphic Labs has added another name to the roster of pharma companies tapping into its AI-based drug discovery engine. Johnson & Johnson's Janssen Biotech unit is the ...
Add Yahoo as a preferred source to see more of our stories on Google. Demis Hassabis speaks during the 56th annual World Economic Forum (WEF) meeting in Davos, Switzerland, January 20, 2026.
Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.
Jan 20 : Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday. The ...
Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.
就在今天，DeepMind拆分的AI制药独角兽Isomorphic Labs宣布，与强生旗下的生物技术部门杨森制药达成合作协议。 在这项合作中，将Isomorphic的AI设计引擎与杨森在药物开发方面的专业知识相结合，共同进行"跨模式、多靶点研究合作"。 根据协议，Isomorphic将负责计算机 ...
A former scientist at Google's DeepMind who co-developed the AlphaFold2 protein prediction platform, Dr Simon Kohl, has launched his own venture applying artificial intelligence to drug discovery.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果